Target intelligence / Profile preview

Fat storage

Molecular classification
Other
01

Overview

Fat storage is a complex physiological process characterized by the synthesis and accumulation of triacylglycerols within specialized lipid droplets of adipocytes [1]. This mechanism is vital for energy homeostasis, as it allows the body to store metabolic fuel during caloric excess and mobilize it during energy deficits [2]. In addition to energy buffering, fat storage in adipose tissue serves as an endocrine organ, secreting signaling molecules like leptin and adiponectin that regulate appetite, insulin sensitivity, and systemic metabolism [3]. While 'Fat storage' is colloquially used to describe a therapeutic focus, it is a physiological pathway and biological state rather than a single molecular target [4]. Pharmacological strategies to address pathological fat storage, such as obesity, involve targeting various specific components including gastrointestinal lipases (e.g., Orlistat), GLP-1 receptors (e.g., Semaglutide), or PPAR-gamma (e.g., Pioglitazone) [1, 5]. Excessive accumulation of fat is a primary driver of chronic metabolic conditions, including type 2 diabetes mellitus, non-alcoholic fatty liver disease (NAFLD), and cardiovascular disease [4].

Other names
Lipid storageAdipogenesisTriacylglycerol accumulationLipogenesisFat deposition
02

Mechanism of action

Modulation of lipid absorption via gastric and pancreatic lipase inhibition, regulation of energy intake through GLP-1 and GIP receptor agonism, and enhancement of lipid storage capacity and insulin sensitivity through PPAR-gamma activation.

03

Biological functions

Lipid metabolismEnergy homeostasisEndocrine signalingThermoregulation
04

Disease associations

ObesityType 2 diabetesCardiovascular diseaseNon-alcoholic fatty liver disease (NAFLD)Metabolic syndrome
05

Safety considerations

Gastrointestinal distress (steatorrhea, nausea)Risk of pancreatitisPotential for fat-soluble vitamin malabsorptionRisk of weight regain upon treatment cessationPotential for hypoglycemia when combined with other metabolic agents
06

Interacting drugs

Orlistat

4 more in the full profile.

07

Biomarkers

Body mass index (BMI)Serum triglyceridesAdiponectin levelsLeptin levelsWaist-to-hip ratio

Beyond the preview

Go deeper on Fat storage.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fat storage.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call